Tempus AI (NASDAQ:TEM) Shares Down 4.2% – Here’s Why

Shares of Tempus AI, Inc. (NASDAQ:TEM) were down 4.2% during trading on Wednesday . The company traded as low as $63.78 and last traded at $63.9820. Approximately 2,057,659 shares were traded during mid-day trading, a decline of 64% from the average daily volume of 5,666,156 shares. The stock had previously closed at $66.78.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. BTIG Research raised their target price on shares of Tempus AI from $96.00 to $105.00 and gave the company a “buy” rating in a research report on Tuesday, November 25th. Piper Sandler reduced their price objective on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating for the company in a research note on Tuesday, November 11th. TD Cowen cut Tempus AI from a “buy” rating to a “hold” rating in a report on Tuesday, October 21st. Canaccord Genuity Group dropped their target price on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, December 22nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tempus AI in a research report on Wednesday, October 8th. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $87.20.

Tempus AI Trading Down 4.4%

The business has a 50 day moving average of $68.87 and a two-hundred day moving average of $73.68. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.05. The firm had revenue of $334.21 million for the quarter, compared to the consensus estimate of $328.89 million. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company’s quarterly revenue was up 84.7% on a year-over-year basis. During the same period in the previous year, the company earned ($0.46) earnings per share. As a group, equities analysts expect that Tempus AI, Inc. will post -6.15 earnings per share for the current year.

Insider Activity at Tempus AI

In other Tempus AI news, CFO James William Rogers sold 19,966 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the transaction, the chief financial officer owned 111,250 shares in the company, valued at $8,143,500. This trade represents a 15.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Ryan Fukushima sold 5,000 shares of Tempus AI stock in a transaction on Monday, January 5th. The stock was sold at an average price of $64.26, for a total value of $321,300.00. Following the sale, the chief operating officer directly owned 148,808 shares of the company’s stock, valued at $9,562,402.08. This represents a 3.25% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 932,832 shares of company stock valued at $71,184,024. Insiders own 26.27% of the company’s stock.

Institutional Trading of Tempus AI

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its position in Tempus AI by 22.1% during the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after purchasing an additional 1,706,837 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its stake in shares of Tempus AI by 1.2% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,504,823 shares of the company’s stock valued at $206,960,000 after purchasing an additional 41,728 shares during the last quarter. Voloridge Investment Management LLC raised its holdings in shares of Tempus AI by 183.0% during the 3rd quarter. Voloridge Investment Management LLC now owns 1,607,083 shares of the company’s stock worth $129,708,000 after buying an additional 1,039,176 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Tempus AI by 0.4% during the 3rd quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company’s stock worth $117,523,000 after buying an additional 5,375 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in Tempus AI by 312.7% in the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock valued at $102,869,000 after buying an additional 965,730 shares in the last quarter. Institutional investors own 24.22% of the company’s stock.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.